HOME >> BIOLOGY >> NEWS
New analyses reinforce efficacy of Remicade in treatment of severe psoriasis

WASHINGTON, DC, February 2, 2007 -- Findings from an integrated analysis of data from three pivotal, randomized, placebo-controlled trials showed that at week 10 more than three-quarters of patients with severe psoriasis receiving REMICADE (infliximab) 3 mg/kg or 5 mg/kg achieved a 75 percent improvement in the chronic, inflammatory skin disease as measured by the Psoriasis Area Severity Index (PASI 75). In addition, in a separate analysis, investigators presented findings from a Phase 3 study, which showed that patients treated with REMICADE experienced significant and progressive improvements in psoriasis affecting the nails. Nail disease occurs in up to 50 percent of people with psoriasis. These findings were presented today at the 65th Annual Meeting of the American Academy of Dermatology.

"The integrated data show the substantial efficacy of REMICADE and present great hope for patients with severe psoriasis, particularly those patients burdened with this chronic disease who previously failed phototherapy or systemic therapy," said Alan Menter, MD, dermatologist, Baylor Research Institute, Dallas, and lead study investigator.

In the analysis of 1462 randomized patients, 991 patients (68 percent) met criteria for severe disease as defined by a body surface area (BSA) of at least 20 percent. Out of the 991 patients, 73 percent and 69 percent of study patients had received previous phototherapy or systemic therapy, respectively. At week 10, among patients with severe psoriasis treated with REMICADE (combined 3 mg/kg and 5 mg/kg groups), 79 percent of patients who had received prior phototherapy and 76 percent who had been previously treated with one or more systemic agents achieved PASI 75, compared with three percent and one percent, respectively, of placebo patients (P < 0.001, for both). In a separate analysis from the Evaluation of Infliximab for Psoriasis in a [REMICADE] Efficacy and Safety Study (EXPRESS II), among patients wit
'"/>

Contact: Brian Kenney
215-620-0111
Centocor, Inc.
2-Feb-2007


Page: 1 2 3 4 5 6

Related biology news :

1. A thesis of the UGR analyses more than 20-million-year-old vegetation to study climatic evolution
2. Cold Spring Harbor Protocols highlights reliable methods for gene and protein analyses
3. Genetic research at Childrens Hospital of Pittsburgh reinforces theory of evolution
4. 16-Year follow-up study reinforces Betaseron long-term efficacy, safety and tolerability in MS
5. New NIST reference material reinforces fragile-x screens
6. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
7. Enhanced MR-guided focused ultrasound guidelines demonstrate improved efficacy and durability
8. Enhancing chemotherapys efficacy: New agent has synergistic effect with standard drugs
9. Tumor response may not be best measure of efficacy in non-small cell lung cancer treatment
10. New 5 year Metvix-PDT data demonstrate long-term efficacy & reliability for NM skin cancer treatment
11. Pramipexole delivered sustained efficacy in clinical trial of patients with Restless Legs Syndrome

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/7/2018)... (PRWEB) , ... August 07, 2018 , ... CallTower ... today their new CT Cloud Voice and SIP solutions. CT Cloud solutions are ... secure, quality voice solution that is far superior to traditional PBX systems, at a ...
(Date:8/1/2018)... ... August 01, 2018 , ... Dr. Asher Kimchi, Founder ... winning recipients of the 2018 IAC Awards at the 23rd World Congress on Heart ... also named four faculty to receive the Distinguished Fellowship Awards. , Dr. Asher Kimchi, ...
(Date:8/1/2018)... , ... August 01, 2018 , ... Visikol CEO Dr. ... services and strong pharmaceutical company partnerships that Visikol will far exceed its original 2018 ... developing its suite of digital pathology tools, whole mount imaging ...
Breaking Biology News(10 mins):
(Date:8/9/2018)... ... August 08, 2018 , ... ... was developed and is continually updated by a talented scientific team that includes ... service provides: , 1. Information on the medical impact of a patient’s ...
(Date:8/9/2018)... ... August 09, 2018 , ... Simpson ... construction (AEC) experts with building owners and managers for a full-day discussion on ... Construct symposium comes to Boston for the first time on Thursday, 13 September ...
(Date:7/31/2018)... (PRWEB) , ... July 31, 2018 , ... ... 2 additional CE/IVD marked molecular quality controls to its expanding CE/IVD product inventory. ... controls to our expanding CE/IVD QC offerings. ZeptoMetrix remains entirely committed to fully ...
(Date:7/25/2018)... ... July 25, 2018 , ... Dimitrius Anagnos, an evidence-based ... combat inflammation and autoimmune disorders. , The preclinical research assessed biomarkers for ... was reported:, Over 70% decrease in Interleukin (IL-1ß) ...
Breaking Biology Technology:
Cached News: